Navigation Links
Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
Date:1/31/2008

SEATTLE, Jan. 31 /PRNewswire/ -- Use of vitamin and mineral supplements among cancer survivors is widespread, despite inconclusive evidence that such use is beneficial, according to a comprehensive review of scientific literature conducted by researchers at Fred Hutchinson Cancer Research Center and published Feb. 1 in the Journal of Clinical Oncology.

"Can vitamin and herbal supplements reduce the adverse effects of cancer treatment, decrease the risk of cancer recurrence or improve a patient's chances of survival? We don't really know. Research into these matters has been minimal," said senior author Cornelia (Neli) Ulrich, Ph.D., an associate member of the Hutchinson Center's Public Health Sciences Division. "While supplement use may be beneficial for some patients, such as those who cannot eat a balanced diet, research suggests that certain supplements may actually interfere with treatment or even accelerate cancer growth," she said.

In reviewing 32 studies conducted between 1999 and 2006, Ulrich and co-author Christine Velicer, Ph.D., formerly a postdoctoral fellow at the Hutchinson Center (now an epidemiologist at Merck Research Laboratory in North Wales, Pa.), found that many of the nation's 10 million adult cancer survivors use nutritional supplements.

They found 64 percent to 81 percent of cancer survivors overall reported using vitamins or minerals (excluding multivitamins), whereas in the general population only 50 percent of adults reported taking dietary supplements.

Survivors of breast cancer reported the highest use (75 percent to 87 percent), whereas prostate-cancer survivors reported the least (26 percent to 35 percent). Factors associated with the highest level of supplement use overall included a higher level of education and being female.

The researchers also found that many people initiate the use of vitamins and supplements after cancer diagnosis; between 14 percent and 32 percent start taking them after learning they have cancer.

"Cancer survivors report that they hope to strengthen their immune system with supplement use or gain a sense of control and empowerment," Ulrich said. However, many cancer survivors who use supplements do not let their doctors know; 31 percent to 68 percent of cancer patients and survivors who use supplements may not disclose this information or their doctors may fail to record it in their charts.

"This is disconcerting and suggests that many physicians may not recognize the importance of understanding whether their patients are taking supplements," Ulrich said.

Knowing about supplement use is crucial, she continues, because of potential adverse effects. "Evidence clearly suggests the need for caution," Ulrich said. "Some vitamins, such as folic acid, may be involved in cancer progression while others, such as St. John's wort, can interfere with chemotherapy. However, we really need more research to understand whether use of these supplements can be beneficial or do more harm than good."

Until research clarifies the effects of vitamin use in cancer survivors, the authors urge health care professionals to communicate openly with their patients about supplement use. "A simple explanation that medical studies show supplement use may not always be beneficial may help cancer survivors make well-informed decisions," the authors wrote.

The National Cancer Institute funded this research.

At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit http://fhcrc.org.

CONTACT

Kristen Woodward

(206) 667-5095

kwoodwar@fhcrc.org


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
2. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
3. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
4. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
5. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
6. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
7. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
8. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
9. Study Examines Media Preferences of Life Scientists in Applied Markets
10. Triage study challenges notions of emergency medical response to disaster
11. Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):